Skip to main content
. 2014 Apr 9;6(2):19. doi: 10.1186/alzrt249

Table 2.

Summary statistics of decreases from baseline in cerebrospinal fluid Aβ 1–42 following administration of GSK933776 a

Sampling time (h) GSK933776 (n= 6/dose) Baseline b Postdosing Change (%) 95% CI
0 to 4
1 mg/kg
363.4 ± 60.1
350.2 ± 61.7
−3.6
(−10.8 to 3.6)
 
3 mg/kg
479.2 ± 65.8
446.4 ± 70.8
−6.8
(−14.9 to 1.2)
 
6 mg/kg
502.7 ± 71.1
456.1 ± 88.9
−9.7
(−15.4 to −3.9)
5 to 12
1 mg/kg
363.4 ± 60.1
333.9 ± 52.1
−7.9
(−12.6 to −3.2)
 
3 mg/kg
479.2 ± 65.8
428.9 ± 77.1
−10.7
(−20.2 to −1.2)
 
6 mg/kg
502.7 ± 71.1
433.5 ± 85.1
−14.2
(−19.8 to −8.6)
0 to 12
1 mg/kg
363.4 ± 60.1
340.6 ± 55.7
−6.2
(−11.2 to −1.1)
 
3 mg/kg
479.2 ± 65.8
435.7 ± 74.4
−9.2
(−17.9 to −0.5)
  6 mg/kg 502.7 ± 71.1 442.2 ± 86.4 −12.5 (−18.0 to −7.0)

aCI: confidence interval. Results are reported as means ± standard deviations. b-6 to −1 hours predosing.